Literature DB >> 28570731

Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach.

Ilse Mombaerts1, Jurij R Bilyk2, Geoffrey E Rose3, Alan A McNab4, Aaron Fay5, Peter J Dolman6, Richard C Allen7, Martin H Devoto8, Gerald J Harris9.   

Abstract

Importance: Current practice to diagnose idiopathic orbital inflammation (IOI) is inconsistent, leading to frequent misdiagnosis of other orbital entities, including cancer. By specifying criteria, diagnosis of orbital inflammation will be improved. Objective: To define a set of criteria specific for the diagnosis of IOI. Design, Setting, and Participants: A 3-round modified Delphi process with an expert panel was conducted from June 8, 2015, to January 25, 2016. Fifty-three orbital scientist experts, identified through membership in the Orbital Society, were invited to participate in on online survey and they scored, using 5-point Likert scales, items that are eligible as diagnostic criteria from the literature and from personal experience. The items were clustered around the anatomic subtypes of IOI: idiopathic dacryoadenitis and idiopathic orbital fat inflammation (2 nonmyositic IOIs), and idiopathic orbital myositis (myositic IOI). Items with dissensus were rescored in the second round, and all items with consensus (median, ≥4; interquartile range, ≤1) were ranked by importance in the third round. Main Outcomes and Measures: Consensus on items to be included in the criteria.
Results: Of the 53 experts invited to participate, a multinational panel of 35 (66%) individuals with a mean (SD) years of experience of 31 (11) years were included. Consensus was achieved on 7 of 14 clinical and radiologic items and 5 of 7 pathologic items related to diagnosis of nonmyositic IOI, and 11 of 14 clinical and radiologic items and 1 of 5 pathologic items for myositic IOI. There was agreement among panelists to focus on surgical tissue biopsy results in the diagnosis of nonmyositic IOI and on a trial with systemic corticosteroids in myositic IOI. Panelists agreed that a maximum number of 30 IgG4-positive plasma cells per high-power field in the orbital tissue is compatible with the diagnosis of IOI. Conclusions and Relevance: An international panel of experts endorsed consensus diagnostic criteria of IOI. These criteria define a level of exclusion suggested for diagnosis and include tissue biopsy for lesions not confined to the extraocular muscles. This consensus is a step toward developing guidelines for the management of IOI, which needs to be followed by validation studies of the criteria.

Entities:  

Mesh:

Year:  2017        PMID: 28570731      PMCID: PMC5710199          DOI: 10.1001/jamaophthalmol.2017.1581

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  27 in total

Review 1.  Idiopathic orbital inflammation with extraorbital extension: case series and review.

Authors:  B Zborowska; R Ghabrial; D Selva; P McCluskey
Journal:  Eye (Lond)       Date:  2006-01       Impact factor: 3.775

2.  Clinical manifestations of orbital mass lesions at the Jules Stein Eye Institute, 1999-2003.

Authors:  Guy J Ben Simon; Michael K Yoon; Jane Atul; Tanuj Nakra; John D McCann; Robert A Goldberg
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2006 Jan-Feb

3.  Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy: The 2005 ASOPRS Foundation Lecture.

Authors:  Gerald J Harris
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2006 Mar-Apr       Impact factor: 1.746

Review 4.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

5.  The meaning of diagnoses in orbital disease.

Authors:  Alon Kahana; Victor M Elner
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Sep-Oct       Impact factor: 1.746

6.  Idiopathic sclerosing orbital inflammation.

Authors:  James D Hsuan; Dinesh Selva; Alan A McNab; Timothy J Sullivan; Peerooz Saeed; Brett A O'Donnell
Journal:  Arch Ophthalmol       Date:  2006-09

Review 7.  What is orbital pseudotumor?

Authors:  I Mombaerts; R Goldschmeding; R O Schlingemann; L Koornneef
Journal:  Surv Ophthalmol       Date:  1996 Jul-Aug       Impact factor: 6.048

Review 8.  Orbital inflammation: Corticosteroids first.

Authors:  Lora R Dagi Glass; Suzanne K Freitag
Journal:  Surv Ophthalmol       Date:  2016-03-10       Impact factor: 6.048

Review 9.  Inflammatory orbital pseudotumor with extension beyond the orbit.

Authors:  Michael A Mahr; Diva R Salomao; James A Garrity
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

10.  An exploration of the use of simple statistics to measure consensus and stability in Delphi studies.

Authors:  Elizabeth A Holey; Jennifer L Feeley; John Dixon; Vicki J Whittaker
Journal:  BMC Med Res Methodol       Date:  2007-11-29       Impact factor: 4.615

View more
  16 in total

Review 1.  Imaging of orbital infectious and inflammatory disease in children.

Authors:  Usha D Nagaraj; Bernadette L Koch
Journal:  Pediatr Radiol       Date:  2021-05-12

2.  Rapid and complete vision loss due to idiopathic orbital inflammation with partial recovery following orbital decompression.

Authors:  Ivan Vrcek; Evan Wotipka; Marie Somogyi; Tanuj Nakra
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-14

Review 3.  Orbital Vasculitides-Differential Diagnosis.

Authors:  Gabriela M Espinoza; Jessica L Liu
Journal:  Curr Rheumatol Rep       Date:  2019-09-05       Impact factor: 4.592

Review 4.  Idiopathic Orbital Myositis Revisited.

Authors:  Ilse Mombaerts; Alan A McNab
Journal:  Curr Rheumatol Rep       Date:  2022-02-09       Impact factor: 4.592

Review 5.  Extraocular muscle enlargement.

Authors:  Khizar Rana; Valerie Juniat; Sandy Patel; Dinesh Selva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.535

6.  The role of ultrasonography in differential diagnosis of orbital lesions.

Authors:  Vittoria Lanni; Adriana Iuliano; Federica Fossataro; Camilla Russo; Giovanni Uccello; Fausto Tranfa; Diego Strianese; Gianfranco Vallone
Journal:  J Ultrasound       Date:  2020-03-12

Review 7.  Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

Authors:  M Marinò; I Ionni; G Lanzolla; A Sframeli; F Latrofa; R Rocchi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-11-05       Impact factor: 5.467

Review 8.  CT and MR imaging of orbital inflammation.

Authors:  Teresa A Ferreira; P Saraiva; S W Genders; M V Buchem; G P M Luyten; J-W Beenakker
Journal:  Neuroradiology       Date:  2018-10-11       Impact factor: 2.804

9.  Acute Proptosis in a Diabetic Patient: Diagnostic and Therapeutic Dilemmas.

Authors:  Ibrahim Khairul-Anwar; Evelyn Tai; Adil Hussein; Embong Zunaina
Journal:  Cureus       Date:  2021-06-10

10.  A pan-inflammatory microRNA-cluster is associated with orbital non-Hodgkin lymphoma and idiopathic orbital inflammation.

Authors:  Kamil G Laban; Rachel Kalmann; Cornelis P J Bekker; Sanne Hiddingh; Rob L P van der Veen; Christine A E Eenhorst; Stijn W Genders; Maarten P Mourits; Fleurieke H Verhagen; Emmerik F A Leijten; Saskia Haitjema; Mark C H de Groot; Timothy R D J Radstake; Joke H de Boer; Jonas J W Kuiper
Journal:  Eur J Immunol       Date:  2019-11-25       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.